Evidence map›Paper›PMID 32492925›Full record

ArticleInternational journal of environmental research and public health2020

Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data.

Valentina Orlando, Sara Mucherino, Ilaria Guarino, Francesca Guerriero, Ugo Trama, Enrica Menditto

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Valentina OrlandoCIRFF, Center of Pharmacoeconomics and Drug utilization Research, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-8209-8878
Sara MucherinoCIRFF, Center of Pharmacoeconomics and Drug utilization Research, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0003-3357-5655
Ilaria GuarinoCIRFF, Center of Pharmacoeconomics and Drug utilization Research, University of Naples Federico II, 80131 Naples, Italy.
Francesca GuerrieroCIRFF, Center of Pharmacoeconomics and Drug utilization Research, University of Naples Federico II, 80131 Naples, Italy.
Ugo TramaRegional Pharmaceutical Unit, Campania Region, 80131 Naples, Italy.
Enrica MendittoCIRFF, Center of Pharmacoeconomics and Drug utilization Research, University of Naples Federico II, 80131 Naples, Italy.
University of Naples Federico II · ITRegione Campania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug prescription in 2018. Prevalence was used as a measure to estimate the degree of exposure to drugs. A total of 3,899,360 patients were treated with at least one drug (54.2% females). The number of prescriptions was higher in females than males (55.6% vs. 44.4%). Females recorded higher prevalence for the majority of therapeutic groups (ATC II-anatomical therapeutic chemical), as well as for anti-inflammatory and antirheumatic products drugs (M01) (25.6% vs. 18.7%, risk ratio (RR): 0.73), beta blocking agents (C07) (14.5% vs. 11.6%, RR: 0.80), psychoanaleptics (N06) (7.1% vs. 3.7%, RR: 0.52), and antianemic preparations (B03) (2.8% vs. 6.7%, RR: 0.4). Higher prevalence was identified for males only for drugs used in diabetes (A10) (6.8% vs. 6.2%, RR: 1.1), particularly for biguanides (A10BA). Conversely, treatment duration was longer among males, explaining the higher mean cost per treated patient. This real-world study showed substantial gender differences in terms of medication use and duration of treatment and costs. These results are relevant to promoting and supporting the emerging role of precision and personalized medicine.

Indexed as

Drug PrescriptionsDrug UtilizationFemaleHumansItalyMaleOdds RatioSex Factorsdrug costdrug utilization studygender differencemedication useprescription patternreal-world data

Identifiers

PMID32492925
PMCPMC7312791
OpenAlexW3030296366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.